Non-Melanoma Skin Cancer (Squamous Cell Carcinoma)
Cutaneous squamous cell carcinoma is a malignant proliferation of epidermal keratinocytes that has breached the basement membrane and acquired the capacity for local tissue invasion and, less commonly, metastasis. As the second most prevalent skin cancer after basal cell carcinoma, it accounts for roughly 20 % of the 4–5 million non-melanoma skin cancers diagnosed annually in the United States. Lesions typically arise on chronically ultraviolet-exposed skin and manifest as indurated, scaly, or keratotic papules, plaques, or nodules that may ulcerate. Although most tumors are detected early and cured surgically, high-risk variants such as those larger than 2 cm, poorly differentiated, deeply invasive, or occurring in immunosuppressed hosts carry a significant risk of regional nodal spread and disease-specific mortality.
Symptoms
Cutaneous squamous cell carcinoma usually begins as a slowly enlarging erythematous or flesh-colored hyperkeratotic plaque or nodule with adherent scale or crust that may fissure, bleed, or develop a central ulcer. Lesions on the lower lip, ear, or scalp often feel tender or painful. Some tumors manifest as warty growths or indurated verrucous masses, while subungual lesions can mimic chronic paronychia. Rapid change in size, persistent non-healing ulceration, paraesthesia in the distribution of a cutaneous nerve, or emergence of a firm regional lymph node are ominous indicators of aggressive behavior. Constitutional symptoms are rare until late metastatic disease.
Risk Factors
Cumulative ultraviolet exposure, especially in equatorial or high-altitude climates, is the dominant risk. Fair skin phototypes I–II, red or blond hair, blue or green eyes, and a history of blistering childhood sunburns confer heightened susceptibility. Additional risks include actinic keratoses, Bowen disease, chronic ulcers or scars (Marjolin ulcer), previous ionizing-radiation therapy, exposure to arsenic or industrial hydrocarbons, cigarette smoking of more than 20 pack-years, male sex, increasing age, solid-organ transplantation with calcineurin-inhibitor immunosuppression, chronic lymphocytic leukemia, HIV infection, epidermolysis bullosa, xeroderma pigmentosum, and carriage of high-risk APOL1 alleles in Black patients.
Diagnosis
Any suspicious lesion warrants full-thickness sampling with shave, punch, or excisional biopsy that includes the deep dermis to gauge invasion depth. Histopathology confirms keratin-pearl formation, intercellular bridges, and variable differentiation. Dermoscopy demonstrates white circles, keratin plaques, and atypical vascular patterns that aid in triage but cannot replace histology. Tumor staging follows the AJCC 8 TNM system, incorporating size, depth ≥ 6 mm or beyond subcutaneous fat, perineural invasion ≥ 0.1 mm, and anatomic high-risk sites such as ear, lip, or temple. Sentinel-node biopsy or ultrasound-guided fine-needle aspiration evaluates clinically occult nodal disease in select high-risk tumors. Cross-sectional imaging with CT or MRI is reserved for deeply invasive, recurrent, or head-and-neck tumors abutting vital structures.
Treatment
Surgical excision with 4–6 mm margins for low-risk tumors and wider or Mohs micrographic surgery for high-risk sites remains the gold standard, yielding five-year cure rates above 95 %. Curettage-and-electrodesiccation, cryosurgery, or photodynamic therapy may suffice for in-situ disease. Radiation therapy provides adjuvant control for positive margins, perineural invasion, or medically inoperable patients and achieves palliation in metastatic cases. Cemiplimab or pembrolizumab, programmed-death-1 inhibitors, are first-line systemic therapies for unresectable or metastatic cSCC, with response rates near 45 %. Cetuximab or platinum-based chemotherapy serve as second-line options. Intralesional methotrexate, topical 5-fluorouracil, or imiquimod treat superficial residual disease. Post-treatment surveillance every 3–12 months detects local recurrence or field-cancerization lesions requiring field therapy with topical agents or resurfacing lasers.
Outlook
When detected early and completely excised, cSCC boasts disease-specific survival exceeding 99 %. Metastasis occurs in 1–4 % overall but rises to 15–20 % in tumors > 2 cm, ≥ 6 mm deep, arising in chronically inflamed skin, or in transplant recipients. Five-year survival after nodal metastasis approximates 50 % and falls below 35 % with distant spread. Programmed-death-1 blockade has improved outcomes in advanced disease, producing durable remissions in roughly one-third of responders. Long-term prognosis also depends on field control, because patients develop a median of six keratinocyte cancers within five years of an index tumor.
Complications
Local tissue destruction may erode cartilage or bone, producing functional and cosmetic impairment; perineural invasion can result in neuropathic pain or facial paralysis; regional nodal metastasis impairs lymphatic drainage, while distant spread to lung, liver, or brain portends poor survival; treatment sequelae include surgical scarring, radiation dermatitis, immune-related adverse events with checkpoint inhibitors, and persistent field cancerization predisposing to additional skin malignancies.
Prevention
Primary prevention focuses on limiting cumulative ultraviolet irradiation through lifelong photoprotection, regulation of artificial tanning devices, and workplace safety standards for outdoor laborers. High-risk groups, including organ-transplant recipients, should undergo annual dermatologic screening, and nicotinamide 500 mg twice daily has demonstrated a 23 % reduction in new keratinocyte cancers in randomized trials. Field therapy of actinic keratoses with topical 5-fluorouracil, imiquimod, or daylight-assisted photodynamic therapy decreases progression to invasive cSCC. Secondary prevention relies on rapid treatment of in-situ lesions, education about warning signs, and continuation of sun-safe behaviors after cure.
Support
Patients benefit from monthly self-skin examinations using mirrors and smartphone photography to document lesions and from engaging family members in hard-to-see areas such as the scalp or back. Adherence to broad-spectrum SPF 30 + sunscreen applied every two hours, sun-protective clothing, wide-brimmed hats, and avoidance of indoor tanning are essential. Immunocompromised patients should coordinate with transplant or oncology teams to optimize immunosuppression, receive shingles and pneumococcal vaccines, and maintain diligent wound care of chronic ulcers. Smoking cessation and alcohol moderation further lower secondary cancer risk.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
